

Certificate of Analysis for NR-55552

Klebsiella pneumoniae, Strain MRSN 401050

Catalog No. NR-55552

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain MRSN 401050 was isolated in 2016 from a human fluid sample in North America as part of a global surveillance program. NR-55552 was deposited as a multidrug-resistant strain, sensitive to amikacin, aztreonam, cefepime, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, ceftriaxone, ertapenem, gentamicin, imipenem, meropenem, tetracycline, tobramycin and tigecycline, intermediately resistant to levofloxacin, and resistant to ampicillin/sulbactam, ciprofloxacin, piperacillin/tazobactam and trimethoprim/sulfamethoxazole. NR-55552 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70050670 Manufacturing Date: 04MAR2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth, mucoid and cream (Figure 1)
Motility (wet mount)	Report results	Non-motile
VITEK® 2 (GN card)	K. pneumoniae (≥ 89%)	K. pneumoniae (99%)
Antibiotic Susceptibility Profile ^{1,2}		
Amikacin	Sensitive	Sensitive (≤ 2 μg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Aztreonam	Sensitive	Sensitive (≤ 1 μg/mL)
Cefepime	Sensitive	Sensitive (≤ 1 μg/mL)
Ceftazidime	Sensitive	Sensitive (≤ 1 μg/mL)
Ceftazidime/avibactam	Sensitive	Sensitive (0.50 µg/mL)
Ceftolozane/tazobactam	Sensitive	Sensitive (0.50 to 1 µg/mL)
Ceftriaxone	Sensitive	Sensitive (≤ 1 μg/mL)
Ciprofloxacin	Resistant	Intermediate (3 µg/mL) ³
Ertapenem	Sensitive	Sensitive (≤ 0.5 μg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 μg/mL)
Imipenem	Sensitive	Sensitive (0.125 to 0.19 µg/mL)
Levofloxacin	Intermediate	Intermediate (4 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Piperacillin/tazobactam	Resistant	Resistant (≥ 128 μg/mL)
Tetracycline	Sensitive	Sensitive (4 μg/mL)
Tigecycline	Sensitive	Sensitive (0.75 to 1 μg/mL) ⁴
Tobramycin	Sensitive	Sensitive (≤ 1 μg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 μg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to K. pneumoniae, strain MRSN 401050 (GenBank: JAGYDH010000094.1)	99.8% sequence identity to K. pneumoniae, strain MRSN 401050 (GenBank: JAGYDH010000094.1) ⁵

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for NR-55552

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

Figure 1: Colony Morphology



/Heather Couch/

Heather Couch 06 MAY 2022

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK®2 GN74 and ETÉST®.

³The susceptibility result for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁴MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁵Also consistent with other *Klebsiella* species